Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Graft vasculopathy and tolerance: does the balance of Th cells contribute to graft vasculopathy?

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Tolerance Induced by IL-6 Deficient Donor Heart is Significantly Involved in Myeloid-Derived Suppressor Cells (Mdscs).

Pronged Graft Survival by IL-6 Deficient Donor is Significantly Involved in Myeloid-Derived Suppressor Cells (MDSCs)

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Presensitized Immune Condition of Host Exaggerates Prolonged Cold Ischemia-Mediated Injury of Cardiac Graft Involving Regulatory T Cells.

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Donor IL-6 Deficiency Evidently Reduces Memory T Cell Responses in Sensitized Transplant Recipients.

Alteration Of Innate Immunity By Donor Il-6 Deficiency In A Presensitized Heart Transplant Model

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.

Graft Protective and Intercellular Immunomodulatory Effects by Adoptive Transfer of an Agonistic Anti-BTLA mAb (3C10) Induced CD4+CD25+ Regulatory T Cells in Murine Cardiac Allograft Transplant Model

Long-term cardiac allograft survival across an MHC mismatch after "pruning" of alloreactive CD4 T cells

Contribution of B Cells and Antibody to Cardiac Allograft Vasculopathy

Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

The Role of Alloantibody in the Development of Cardiac Allograft Vasculopathy.

The Relationship Between Th1/Th2 Cytokines Mrna Expression and Immune Tolerance to Cardiac Allografts in Rats

[Effect of T suppressor cells on the maintenance phase of tolerance to cardiac allografts in the rats].

TGF-beta(1) gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo.

ALTERATIONS OF T CELL SIGNALING PATHWAYS IN ALLOGENEIC RAT HOSTS RENDERED TOLERANT BY ORAL ADMINISTRATION OF ALLOCHIMERIC CLASS I MHC PROTEINS

Cyclosporine Immunosuppression Does Not Prevent the Production of Donor-Specific Antibody Capable of Mediating Allograft Vasculopathy.

[Induced Tolerance to Cardiac Allografts with Intrathymic Injection of Donor Spleen Cells].